Pre-screening study for ovarian cancer after platinum treatment
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial is a pre-screening process for people with ovarian cancer whose disease came back quickly after platinum chemotherapy (or who cannot take platinum). It may help match you to future study options using a tumor tissue sample.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ovarian cancer confirmed by a pathology test (looking at tissue under a microscope)
- Your cancer is “platinum-resistant,” meaning it grew again within 6 months after your last platinum chemotherapy dose, or you cannot take platinum
- You have had no more than one previous treatment before this platinum-resistant/ineligible situation
- You have a tumor tissue sample available in FFPE (a preserved form used for testing)
- Your cancer was not “platinum-refractory,” meaning it kept progressing during your most recent platinum chemotherapy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at genetic and other factors that may explain why some people with ovarian cancer respond well to platinum-based chemotherapy for many years, while others do not respond at all. The goal is to better understand these differences to improve future treatments.
This study tests a new drug (INCB123667) given as a pill, compared to standard chemotherapy, for people whose ovarian cancer has stopped responding to platinum-based treatments and whose tumor has high levels of a protein called Cyclin E1. The goal is to see if the new drug works better than standard chemo for this specific type of cancer.
This study is looking for new ways to treat ovarian cancer that has become resistant to current therapies. By joining, you may help researchers develop better treatment options for women like you.
This trial tests a new combination of drugs (trastuzumab rezetecan and carboplatin, with or without bevacizumab) against standard chemotherapy for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer. It’s for those who have already had platinum-based chemo and a PARP inhibitor, and whose cancer came back after a treatment-free interval of at least 6 months.
This Phase 2 study tests an immunotherapy approach for women whose high-grade serous ovarian cancer came back within 6 months of platinum chemotherapy. It may help shrink tumors and improve control of the disease, but you’ll need tumor biopsies and lab/heart/lung checks to join.
This study looks at certain “DNA repair traits” (called homologous recombination phenotype) in people with epithelial ovarian cancer. Results may help researchers better understand who responds to platinum chemotherapy, which is commonly used for this cancer.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.